ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

nilotinib

Also written as “Nilotinib”, “AMN107” and “Tasigna”.

Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Gastrointestinal Stromal Tumors · Neoplasms · Leukemia, Myeloid, Chronic-Phase · Leukemia, led by 3 companies.

Drug pageNilotinib: every studyAll 134 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 19, 200857 company-led studies, 1 open or runningNext primary completion: Aug 30, 2030 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis541 open or runningphase 4since Sep 19, 2008May 2, 2005Aug 30, 2030phase 4 · NCT04877522
Xspray Pharma ABits history only20 open or runningphase 1since Jul 29, 2025Jul 29, 2025none ahead
XSpray Microparticlesits history only10 open or runningphase 1since Feb 19, 2014Feb 19, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 39 studies since May 2, 2005.

  1. May 23, 2012Phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT01605981 · Brazil
  2. Oct 1, 2012Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT01698905 · 163 enrolled · United States, Argentina, Australia and more
  3. Nov 14, 2012Phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT01735955 · 57 enrolled · United States, Austria, Canada and more
  4. Dec 4, 2012Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT01743989 · 620 enrolled · Austria, Belgium, Bulgaria and more
  5. Dec 5, 2012Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT01744665 · 59 enrolled · United States
  6. Jan 30, 2013Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT01784068 · 215 enrolled · United States, Argentina, Austria and more
  7. Apr 29, 2013Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT01844765 · 59 enrolled · United States, France, Hungary and more
  8. May 23, 2013Phase 2 study in Gastrointestinal Stromal TumorsNCT01863745 · 15 enrolled · Japan
  9. Apr 7, 20142 phase 3 studiesNCT02108951, NCT02115386
  10. Sep 17, 2014Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT02253277 · 5 enrolled · Germany
  11. Oct 21, 2014Phase 3 study in LeukemiaNCT02272777 · 225 enrolled · China
  12. Sep 9, 2015Phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT02546674 · 171 enrolled · Germany
  13. Mar 5, 2019Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT03874858 · 135 enrolled · Italy
  14. May 4, 2021Phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04877522 · 347 planned · United States, Argentina, Austria and more

Ahead

  1. Aug 30, 2030Primary completion: phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04877522

TargetBeta

ABL1 →BCR →read by rule
“Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
imatinibruleNovartisphase 470
asciminibruleNovartisphase 416
olverembatinibruleAscentage Pharma Group Internationalphase 310
EmbibatinibHansoh Pharmaceutical Groupphase 37
TQB3911Sino Biopharmaceuticalphase 11

Studies

All 54 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04877522Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Austria and more4RecruitingAug 30, 2030347
NCT03874858Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Italy2TerminatedOct 15, 2025135
NCT02546674Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany4CompletedFeb 23, 2021171
NCT02272777Leukemia · China3CompletedJan 30, 2017225
NCT02253277Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany1CompletedMar 6, 20185
NCT02115386Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Russian Federation3TerminatedOct 31, 20167
NCT02108951Leukemia · Australia3TerminatedAug 10, 201620
NCT01863745Gastrointestinal Stromal Tumors · Japan2CompletedOct 2, 202315
NCT01844765Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, France, Hungary and more2CompletedJun 1, 201659
NCT01784068Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Austria and more2CompletedMay 31, 2016215
NCT01744665Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States2CompletedSep 28, 201859
NCT01743989Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Austria, Belgium, Bulgaria and more3CompletedJul 8, 2020620
NCT01735955Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Austria, Canada and more4CompletedJul 7, 202357
NCT01698905Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Australia and more2CompletedNov 26, 2015163
NCT01605981Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Brazil4WithdrawnJan 20170
NCT01368523Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Poland4CompletedJan 201019
NCT01289028Gastrointestinal Stromal Tumors · Germany, Italy3CompletedJul 2014125
NCT01275196Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China3CompletedOct 2014267
NCT01274351Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Turkey2CompletedAug 1, 2019112
NCT01279473Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Japan2CompletedDec 200942
NCT01254188Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Algeria, Argentina, Australia and more3CompletedNov 2014421
NCT01227577Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States4CompletedNov 2014128
NCT01223898Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany, United Kingdom1CompletedDec 201319
NCT01220648Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany1CompletedJan 20144
NCT01206088CML · Korea, Republic of4CompletedSep 201293
NCT01179737Pulmonary Arterial Hypertension · United States, Canada, Germany and more2TerminatedJan 201323
NCT01131325Leukemia, Myeloid, Chronic-Phase · United States4TerminatedMay 12, 20113
NCT01126892Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Colombia, Venezuela3CompletedApr 20116
NCT01110668Gastrointestinal Stromal Tumors · Turkey2CompletedSep 20112
NCT01077544Leukemia, Myelogenous, Chronic, BCR-ABL Positive · France, Italy, Netherlands and more1CompletedJul 1, 201515
NCT01061177Leukemia · Austria, Belgium, Bulgaria and more4CompletedJul 20141,090
NCT01043874Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Japan4CompletedDec 201345
NCT01028222Melanoma · United States, Argentina, Australia and more2CompletedDec 201455
NCT00980018Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada4CompletedDec 201252
NCT00802841Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Argentina, Brazil, China and more3CompletedJul 2014191
NCT00786812Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Brazil4CompletedJan 201289
NCT00785785Gastrointestinal Stromal Tumors · United States, Argentina, Austria and more3CompletedOct 2014644
NCT00760877Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Argentina, Australia, Brazil and more3CompletedJul 2015207
NCT00756509Gastrointestinal Stromal Tumors · Finland, France, Germany and more4CompletedDec 18, 202434
NCT00751036Gastrointestinal Stromal Tumors · Argentina, Brazil, Canada and more3TerminatedAug 201294
NCT00718562Gastrointestinal Stromal Tumors · Japan2CompletedJul 201335
NCT00644878Leukemia, Myeloid, Chronic-Phase · United States2TerminatedMar 201218
NCT00633295Gastrointestinal Stromal Tumors · Israel2CompletedMay 20109
NCT00519090Leukemia, Myeloid · United States, Australia, Belgium and more3TerminatedOct 20086
NCT00471497Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Austria and more3CompletedSep 2, 2009846
NCT00471328Gastrointestinal Stromal Tumors · United States, Australia, Austria and more3CompletedAug 2008248
NCT00441155Gastrointestinal Stromal Tumors · United States, France, Italy1CompletedJan 201114
NCT00418769Healthy1CompletedAug 200624
NCT00418756Healthy1CompletedNov 200612
NCT00418626Healthy · United States1CompletedSep 200727
NCT00384228Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Japan2CompletedJan 200742
NCT00264160Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Israel3CompletedNov 200836
NCT00135005Gastrointestinal Stromal Tumors · United States, France, Germany and more1CompletedNov 200659
NCT00109707Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Austria and more2CompletedSep 2012507

How it is read

Names in the registry

  • “Nilotinib”, 35 entries
  • “nilotinib”, 9 entries
  • “AMN107”, 3 entries
  • “Tasigna”, 2 entries
  • “Nilotinib (AMN107)”, 2 entries

Codes read as this program: XS003.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.